News | April 13, 2021
Merck publishes sustainability report for 2020
The company is pursuing specific goals in the areas of science and technology, value chain as well as climate and the environment.
The company is pursuing specific goals in the areas of science and technology, value chain as well as climate and the environment.
PegIFN in COVID19 has several add-on advantages compared to other anti-viral agents
Has signed a 12-year, off-site, virtual power purchase agreement (VPPA) with Enel Green Power
The next phase of growth in pharma depends on the industry-oriented workforce, risk investment, academic revamp, and creation of R&D hubs, say experts .
Merck forecasts organic growth of EBITDA pre in a high single-digit to low teens percentage range in 2021.
Total incremental sales of Rs.2,94,000 crore and total incremental exports of Rs.1,96,000 crore are estimated during six years from 2022-23 to 2027-28.
The Govt. launched the PLI scheme for bulk drugs with a financial outlay of Rs 6,940 crores across 53 APIs over 6 years.
While top industry leaders are optimistic about the growth, they expect the special incentives and regulatory streamlining from the government’s side
Applied Biosystems CoviPath COVID-19 RT-PCR Kit is approved for in vitro diagnostic use by ICMR and DCGI.
The Department has been working continuously to ensure a stable long-term policy environment and reduce the compliance burden on the Industry.
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
